Clinical and Experimental Allergy最新文献

{"title":"Prevalence of Feeding Difficulties in Children With Non-IgE Mediated Food Allergies: A Systematic Review.","authors":"Marianne Louise Tomlin, Cassandra Bendall, Paxton Loke, Christie Jane Bennett","doi":"10.1111/cea.70367","DOIUrl":"10.1111/cea.70367","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":"1117-1124"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13532976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148315990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Dose Intravenous Challenge Testing to Neuromuscular Blocking Agents: A Safe and Effective Approach to the Investigation of Perioperative Anaphylaxis. Comment on Clin Exp Allergy 2026;56:438-441.","authors":"Siraj A Misbah, Rachel C Pollard","doi":"10.1111/cea.70390","DOIUrl":"10.1111/cea.70390","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":"1142-1143"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13532980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148403963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Basophil Histamine Content as a Biomarker for Omalizumab Responsiveness in Chronic Spontaneous Urticaria","authors":"Ditte Georgina Zhang, Katrine Baumann, Clive Grattan, Per Stahl Skov, Simon Francis Thomsen","doi":"10.1111/cea.70327","DOIUrl":"10.1111/cea.70327","url":null,"abstract":"<p>Patients with chronic spontaneous urticaria (CSU) exhibit varying treatment needs to achieve disease control with omalizumab, and adjustments to the standard dose of 300 mg every 4 weeks are common [<span>1</span>]. This calls for biomarkers that may aid physicians in tailoring a more personalised treatment approach [<span>2</span>]. Currently, no reliable biomarkers are available for this purpose. The basophil histamine release assay (BHRA) remains the single best biomarker for identifying (autoimmune) type IIb CSU, which tends to respond slower and less effectively to omalizumab treatment compared to (autoallergic) type I CSU [<span>3, 4</span>]. A previous study reported that low intracellular histamine content in basophils is associated with features of type IIb CSU [<span>5</span>]. This study therefore aimed to explore whether intracellular histamine content of basophils could serve as a stronger or complementary novel biomarker for predicting and monitoring treatment response, offering a simpler and less costly alternative to the BHRA.</p><p>A total of 164 adults with CSU who had total cellular blood histamine levels measured were included from the Chronic Urticaria COPenhagen cohort (CU-COP). Details on cohort recruitment and methods for assessing treatment response have been described previously [<span>1</span>]. Informed consent was obtained from all patients and approval was granted by local authorities (Ref. P-2020-318). According to Danish legislation, ethical committee approval was not required. Total cellular blood histamine levels were used to calculate the intracellular histamine content per basophil, as described in detail elsewhere [<span>3</span>]. Continuous variables are presented as medians with interquartile ranges (IQR), and categorical variables as proportions. Correlations between numerical variables were assessed using Spearman's rank correlation coefficient. Group differences were evaluated using the Wilcoxon rank-sum test, with a <i>p</i>-value < 0.05 considered statistically significant. All analyses were performed using <i>R</i> version 4.4.1 and R Studio.</p><p>Clinical characteristics of the study cohort are presented in the repository material. The previously reported association between intracellular histamine content per basophil and features of type IIb CSU was replicated. Among the entire cohort, 106 patients initiated omalizumab treatment, of whom 101 were omalizumab-naïve at baseline. Among these intracellular histamine content per basophil did not differ significantly across patients with fast (within 1 month), delayed (within 3 months) and late/non-response (after 3 months or no response during treatment) to treatment (Figure 1A). Likewise, the intracellular histamine content per basophil did not differ significantly across the overall treatment response groups when comparing patients with good (symptom-free or minor symptoms), partial (insufficient response) and poor response (no response) (Figure","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"1101-1103"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70327","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asthma and Multimorbidity Amongst Ethnic Minority Groups in High Income Countries","authors":"Mamidipudi Thirumala Krishna,&nbsp;Saibal Moitra,&nbsp;Anna Freeman,&nbsp;Ben Ainsworth,&nbsp;Rebecca Knibb,&nbsp;Ramesh Kurukulaaratchy,&nbsp;Adel H. Mansur","doi":"10.1111/cea.70329","DOIUrl":"10.1111/cea.70329","url":null,"abstract":"<p>Asthma is one of the commonest noncommunicable diseases worldwide. Poor clinical outcomes have been reported in asthma amongst ethnic minority groups (EMGs) and reasons are likely to be multifactorial. There is a suggestion that underlying disease may behave differently amongst EMGs, alongside other factors including deprivation, cultural, religious, social, literacy, patient beliefs, healthcare access, treatment adherence, alongside greater burden of multimorbidity. Multimorbidity (presence of ≥ 2 long-term health conditions) in asthma is increasingly known to contribute to greater asthma burden, with differences in multimorbidity burden and patterns seen across ethnicities with a tight association with deprivation. Earlier onset of multimorbidity with relatively reduced survival has been reported amongst EMG patients, particularly those from a deprived background compared to White patients. Data regarding asthma, multimorbidity and ethnicity are scant, but emerging data suggest that multimorbidity is heterogenous, and that ethnic background is associated with variations in asthma outcomes and multimorbidity phenotypes. What is currently lacking is population-based research with a joined-up interrogation of primary care and secondary care databases to determine the prevalence and patterns of T2 and non T2 multimorbidity in asthma amongst EMGs, and analysis of patterns of associations and link to socio-demographic variables and clinical outcomes. Deeper insight into views of EMG patients and their carers regarding lived experiences of asthma and multimorbidity management, as well as those of healthcare professionals is needed, to allow development of culturally tailored resources. These studies are likely to shape a holistic culturally tailored multidimensional and an equitable approach to management of asthma with multimorbidity amongst EMGs.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"1031-1047"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70329","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147940044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Worldwide Impact of Human Development and Inequality on the Prevalence of Asthma, Rhinoconjunctivitis and Eczema. Global Asthma Network's Ecological Study","authors":"Luis García-Marcos,&nbsp;Chen-Yuan Chiang,&nbsp;M. Innes Asher,&nbsp;Guy B. Marks,&nbsp;Asma El Sony,&nbsp;Refiloe Masekela,&nbsp;Karen Bissell,&nbsp;Eamon Ellwood,&nbsp;Philippa Ellwood,&nbsp;Neil Pearce,&nbsp;David P. Strachan,&nbsp;A. Elena Martínez-Torres,&nbsp;Manuel Sánchez-Solís,&nbsp;Kevin Mortimer,&nbsp;Eva Morales,&nbsp;The Global Asthma Network Phase I Study Group","doi":"10.1111/cea.70355","DOIUrl":"10.1111/cea.70355","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lower-income countries have lower asthma prevalence. However, how differences in human development and inequality can explain changes in the prevalence of asthma and allergic diseases is not known.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Global Asthma Network Phase I study reported prevalence of asthma and allergic diseases in children (6–7 years), adolescents (13–14 years), and their parents/guardians in 16, 25 and 17 countries. Gini inequality index (GinI) and human development index (HDI), together with mean annual relative humidity and temperature, and latitude, were used as potential explanatory factors of prevalence differences using meta-regression models, fitted values and heatmaps of prevalence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>GinI and HDI explained some proportion of asthma prevalence variability, which was highest in children (up to ~70% for disease indicators such as current wheeze or symptoms of severe asthma) and lowest in adolescents (~22% for symptoms of severe asthma or asthma ever). Rhinoconjunctivitis prevalence variability was poorly explained by covariates (from ~53% for current rhinoconjunctivitis among children—an exception—to none). Eczema indicators were explained in a range from ~60% in children (current eczema symptoms and symptoms of severe eczema) to ~12% in adolescents (current eczema symptoms). Overall, heatmaps showed areas of higher prevalence in the intersection of high GinI and high HDI values.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>HDI and Gini explain part of the worldwide variability in the prevalence of asthma, rhinoconjunctivitis, and eczema. This explanatory power is highest for asthma and lowest for rhinoconjunctivitis. Lower-resourced communities in highly developed countries show the greatest hazard, particularly for asthma.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"56 9","pages":"1048-1062"},"PeriodicalIF":5.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70355","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148162031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcutaneous Allergen Immunotherapy With Thermosensitive Hydrogel and Recombinant Birch Pollen Allergen Variant, a Randomised Controlled Trial.","authors":"Anna Nilson, Patricia Couroux, Jaana Haka, Silja Halme, Pekka Mattila, R J Joost van Neerven, Rolien Pels-Rijcken, Janneke Ruinemans-Koerts, Yvonne Schmidt-Hieltjes, Anne Marie Salapatek, Kati Sallinen, Kristiina Takkinen, Daphne Tsitoura, Dirk-Jan Opstelten, Juha Rouvinen","doi":"10.1111/cea.70424","DOIUrl":"https://doi.org/10.1111/cea.70424","url":null,"abstract":"<p><strong>Background: </strong>This paper reports a Phase 1, randomised, placebo-controlled, dose-escalation trial (NCT06037148) with DM-101PX that contains a recombinant hypoallergenic Bet v 1 variant formulated with thermosensitive hydrogel. The objectives of the study included assessment of treatment-related adverse events and the number of participants reaching the maximum dose. In addition, Bet v 1-specific immunoglobulins were analysed to explore the immunological effects of treatment. The trial was funded by Desentum Oy.</p><p><strong>Methods: </strong>The study included three cohorts differing in starting and maximum dose. Per cohort, subjects were randomised (4:1) to receive 10 weekly subcutaneous injections with DM-101PX or placebo. Main inclusion criteria comprised adult subjects with a birch pollen allergy for ≥ 2 years, positive skin prick test, birch pollen-IgE ≥ 0.7 kU/L and symptoms upon exposure to birch pollen. The randomisation schedule was generated using software. During the trial, the investigator, clinic staff, participants and sponsor remained blinded to the treatment groups. The primary endpoint was the occurrence of treatment emergent adverse events and adverse events of special interest.</p><p><strong>Results: </strong>In each cohort, 10 subjects were randomised and all were used for analysis of safety data. Treatment-related adverse events were reported by 22/24 (91.7%) DM-101PX treated subjects and by 5/6 (83.3%) placebo-treated subjects, which were only of mild or moderate intensity. The DM-101PX and placebo-treated subjects had mainly local injection site reactions, 138/153 (90.2%) and 22/24 (91.2%), respectively. Fifteen systemic allergic reactions were reported by 5/24 (20.8%) DM-101PX-treated subjects, and 2 systemic allergic reactions were reported by 1/6 (16.7%) placebo-treated subject, all of which were of Grade 1. 21/24 (88%) of subjects reached the maximum dose. Treatment with DM-101PX induced pronounced levels of Bet v 1-specific IgG₄ and post-treatment sera effectively blocked basophil activation.</p><p><strong>Conclusions: </strong>This small study demonstrated that DM-101PX was generally well tolerated and induced a strong and functional immune response.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Immunotherapy for Food-Allergic Patients: Real-World Barriers.","authors":"Christy Wing Man Leung, Nam Sze Cheng, Ting Fan Leung","doi":"10.1111/cea.70425","DOIUrl":"https://doi.org/10.1111/cea.70425","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small Airway Dysfunction Affects One in Five Indian Adolescents: The Multicity APEAL Study.","authors":"Mohammed Kaleem Ullah, Anant Mohan, Rajesh Kumar Thimmulappa, Harish Chandra Phuleria, Santu Ghosh, Rajesh Majumder, Swapnali Patil, Priya Samdarshi, Sathish Chandran Mayigaiah, Ashwaghosha Parthasarathi, Jayaraj Biligere Siddaiah, Twinkle Agrawal, George D'Souza, Padukudru Anand Mahesh","doi":"10.1111/cea.70423","DOIUrl":"https://doi.org/10.1111/cea.70423","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sitting Time and Physical Activity Correlate With Asthma Exacerbations in Adults: A Cross-Sectional Study From the Australasian Severe Asthma Network.","authors":"Chang Yong Wang, Ji Wang, Peng Gao, Wei Jie Zhang, Min Xie, Gang Liu, Ling Qin, Zhi Hong Chen, Dan Liu, Jie Zhang, Feng Ming Luo, Wei Min Li, Gang Wang, Lisa G Wood","doi":"10.1111/cea.70421","DOIUrl":"https://doi.org/10.1111/cea.70421","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2026-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the Oral Mucosa With Egg Protein Effectively Prevents Egg Allergy in Mice.","authors":"Yuya Yoshida, Ryohei Shibao, Hiroki Urakawa, Hikaru Fuchita, Yusei Kiuchi, Mina Iwata, Norihisa Mikami, Ryoji Kawakami, Hirohito Kita, Takumi Tsuji","doi":"10.1111/cea.70422","DOIUrl":"https://doi.org/10.1111/cea.70422","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.0,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}